Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1914 1
1919 1
1948 1
1949 1
1950 7
1951 4
1952 7
1953 7
1954 11
1955 8
1956 8
1957 11
1958 9
1959 8
1960 1
1961 1
1962 15
1963 10
1964 5
1965 6
1966 10
1967 15
1968 11
1969 10
1970 11
1971 11
1972 10
1973 12
1974 11
1975 10
1976 10
1977 14
1978 6
1979 12
1980 5
1981 2
1982 7
1983 3
1984 6
1985 4
1986 8
1987 10
1988 13
1989 7
1990 14
1991 12
1992 7
1993 8
1994 8
1995 9
1996 8
1997 11
1998 12
1999 13
2000 8
2001 5
2002 14
2003 10
2004 14
2005 17
2006 16
2007 20
2008 25
2009 28
2010 32
2011 29
2012 42
2013 29
2014 35
2015 41
2016 42
2017 52
2018 51
2019 57
2020 77
2021 82
2022 84
2023 68
2024 81
2025 77
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,387 results

Results by year

Filters applied: . Clear all
Page 1
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313.
Nyberg WA, Wang CH, Ark J, Liu C, Clouden S, Qualls A, Caryotakis S, Wells E, Simon K, Garza C, Bernard PL, Lopez-Ichikawa M, Li Z, Seo J, Kimmerly GR, Muldoon JJ, Chen PA, Li M, Liang HE, Kersten K, Rosales A, Kuhn N, Ye CJ, Gardner JM, Molofsky A, Ricardo-Gonzalez RR, Asokan A, Eyquem J. Nyberg WA, et al. Among authors: simon k. Immunity. 2025 Feb 11;58(2):499-512.e7. doi: 10.1016/j.immuni.2025.01.009. Epub 2025 Feb 4. Immunity. 2025. PMID: 39909036 Free article.
A molecular mechanism to diversify Ca2+ signaling downstream of Gs protein-coupled receptors.
Brands J, Bravo S, Jürgenliemke L, Grätz L, Schihada H, Frechen F, Alenfelder J, Pfeil C, Ohse PG, Hiratsuka S, Kawakami K, Schmacke LC, Heycke N, Inoue A, König G, Pfeifer A, Wachten D, Schulte G, Steinmetzer T, Watts VJ, Gomeza J, Simon K, Kostenis E. Brands J, et al. Among authors: simon k. Nat Commun. 2024 Sep 3;15(1):7684. doi: 10.1038/s41467-024-51991-6. Nat Commun. 2024. PMID: 39227390 Free PMC article.
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.
Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR, Falconer T, Richter LR, Ostropolets A, Lau WCY, Man KKC, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager SL, Chai Y, Zhou JJ, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie MJ, Ryan PB, Krumholz HM, Hripcsak G, Khera R, Suchard MA. Morales DR, et al. Among authors: simon kr. Diabetes Care. 2025 Aug 1;48(8):1386-1394. doi: 10.2337/dc25-0154. Diabetes Care. 2025. PMID: 40465422 Free PMC article.
Adolescent Substance Use Disorders.
Simon KM, Levy SJ, Bukstein OG. Simon KM, et al. NEJM Evid. 2022 Jun;1(6):EVIDra2200051. doi: 10.1056/EVIDra2200051. Epub 2022 May 24. NEJM Evid. 2022. PMID: 38319247 Free PMC article. Review.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: simon kg. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
Khera R, Aminorroaya A, Dhingra LS, Thangaraj PM, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand TV, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr DA, Duarte-Salles T, DuVall SL, Falconer T, French TE, Hanchrow EE, Kaur G, Lau WCY, Li J, Li K, Liu Y, Lu Y, Man KKC, Matheny ME, Mathioudakis N, McLeggon JA, McLemore MF, Minty E, Morales DR, Nagy P, Ostropolets A, Pistillo A, Phan TP, Pratt N, Reyes C, Richter L, Ross JS, Ruan E, Seager SL, Simon KR, Viernes B, Yang J, Yin C, You SC, Zhou JJ, Ryan PB, Schuemie MJ, Krumholz HM, Hripcsak G, Suchard MA. Khera R, et al. Among authors: simon kr. J Am Coll Cardiol. 2024 Sep 3;84(10):904-917. doi: 10.1016/j.jacc.2024.05.069. J Am Coll Cardiol. 2024. PMID: 39197980 Free PMC article.
How Carvedilol activates β2-adrenoceptors.
Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D, Szpakowska M, Monteleone S, Grimes J, Koszegi Z, Lanoiselée Y, O'Brien S, Pavlaki N, Dobberstein N, Inoue A, Nikolaev V, Calebiro D, Chevigné A, Sasse P, Schulz S, Hoffmann C, Kolb P, Waldhoer M, Simon K, Gomeza J, Kostenis E. Benkel T, et al. Among authors: simon k. Nat Commun. 2022 Nov 19;13(1):7109. doi: 10.1038/s41467-022-34765-w. Nat Commun. 2022. PMID: 36402762 Free PMC article.
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V. Vogel A, et al. Among authors: simon k. Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2. Lancet Gastroenterol Hepatol. 2021. PMID: 34087115 Clinical Trial.
1,387 results